Evidence map›Paper›PMID 26039320›Full record

ArticleAmerican journal of respiratory cell and molecular biology2016

Lipoxin Signaling in Murine Lung Host Responses to Cryptococcus neoformans Infection.

Jennifer K Colby, Katherine M Gott, Julie A Wilder, Bruce D Levy

Abstract readComparative Study
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Inbred Mouse Models inJournal of fungi (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Neutrophils: Beneficial and Harmful Cells in Septic Arthritis.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer K Colby1 Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and.ORCID http://orcid.org/0000-0003-1656-2633
Katherine M Gott2 Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Julie A Wilder2 Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Bruce D Levy1 Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and.
Brigham and Women's Hospital · USLovelace Respiratory Research Institute · US

Funding

RESPIRATORY RESEARCHT32HL007633 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI George R Washko · 1985 to 2026
$14.9M
Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8M
Specialized Pro-Resolving Mediators in AsthmaR01HL122531 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEVY, BRUCE D · 2014 to 2024
$4.7M
Monitoring peripheral blood leukocyte and immune responses in health and diseaseU24AI118656 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LEVY, BRUCE D, VOLDMAN, JOEL · 2015 to 2019
$1.9M
NHLBI NIH HHS 5T32 HL007633-27NHLBI NIH HHS HL66869NHLBI NIH HHS R01 HL122531NHLBI NIH HHS T32 HL007633NIAID NIH HHS U24 AI118656NIGMS NIH HHS P01 GM095467NIGMS NIH HHS P01-GM095467
6 · The paper itself

Abstract

Lipoxins (LX) are proresolving mediators that augment host defense against bacterial infection. Here, we investigated roles for LX in lung clearance of the fungal pathogen Cryptococcus neoformans (Cne). After intranasal inoculation of 5,000 CFU Cne, C57BL/6 and C.B-17 mice exhibited strain-dependent differences in Cne clearance, immunologic responses, and lipoxin A4 (LXA4) formation and receptor (ALX/FPR2) expression. Compared with C.B-17 mice, C57BL/6 lungs had increased and persistent Cne infection 14 days after inoculation, increased eosinophils, and distinct profiles of inflammatory cytokines. Relative to C.B-17 mice, bronchoalveolar lavage fluid levels of LXA4 were increased before and after infection in C57BL/6. The kinetics for 15-epi-LXA4 production were similar in both strains. Lung basal expression of the LX biosynthetic enzyme Alox12/15 (12/15-lipoxygenase) was increased in C57BL/6 mice and further increased after Cne infection. In contrast, lung basal expression of the LXA4 receptor Alx/Fpr2 was higher in C.B-17 relative to C57BL/6 mice, and after Cne infection, Alx/Fpr2 expression was significantly increased in only C.B-17 mice. Heat-killed Cne initiated lung cell generation of IFN-γ and IL-17 and was further increased in C.B-17 mice by 15-epi-LXA4. A trend toward reduced Cne clearance and IFN-γ production was observed upon in vivo administration of an ALX/FPR2 antagonist. Together, these findings provide the first evidence that alterations in cellular immunity against Cne are associated with differences in LXA4 production and receptor expression, suggesting an important role for ALX/FPR2 signaling in the regulation of pathogen-mediated inflammation and antifungal lung host defense.

Indexed as

Signal TransductionAnimalsArachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseBronchoalveolar Lavage FluidChemotaxis, LeukocyteCryptococcosisCryptococcus neoformansHost-Pathogen InteractionsImmunity, CellularInterferon-gammaInterleukin-17KineticsLipoxinsLungLung Diseases, Fungal12-15-lipoxygenaseArachidonate 12-LipoxygenaseArachidonate 15-Lipoxygenaseformyl peptide receptor 2, mouseInterferon-gammaInterleukin-17lipoxin A4LipoxinsOligopeptidesReceptors, Formyl Peptidetryptophyl-arginyl-tryptophyl-tryptophyl-tryptophyl-tryptophanamideALX/FPR2Cryptococcus neoformanslipoxin A4pneumoniaresolution

Identifiers

PMID26039320
PMCPMC4742922
OpenAlexW1760495174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.